Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Teva Pharmaceutical Industries Ltd.
Industry Sector: HealthTechnology
CEO: Richard Francis
Number Of Employees: 36,167
Enterprise Value: $40,140,240,000
PE Ratio: -9.39
Exchange/Ticker 1: NYSE:TEVA
Exchange/Ticker 2: Tel Aviv:TEVA
Latest Market Cap: $15,571,965,952
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 18, 2025
Politics, Policy & Law
Diabetes, cancer drugs dominate CMS’s new price negotiation list
Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027
BioCentury | Dec 20, 2024
Product Development
Long-awaited FDA approval for Mesoblast marks a first in the U.S.
Nearly a decade after Japanese approval, mesenchymal stromal cell therapy approved for pediatric GvHD
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Dec 18, 2024
Product Development
Teva-Sanofi showcase best-in-class TL1A potential, without a biomarker
Duvakitug leads to clinical remission in nearly half of UC patients
BioCentury | Sep 19, 2024
Management Tracks
EMA names Sepodes CHMP chair, Bell leaving Valo as CEO, and more
Plus: Autolus hires Matthias Will as CDO, and updates from HotSpot, Prilenia, Frazier, BIA and BioCentriq
BioCentury | Jul 19, 2024
Management Tracks
Remembering Lisa Burns, biotech’s ‘CEO whisperer’
An IR/PR pioneer, Burns connected CEOs, investors and analysts and played host to JPM’s best party
BioCentury | May 22, 2024
Market Access
What’s behind CVS’s changing adalimumab strategy
Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira
BioCentury | May 16, 2024
Deals
With Proteologix takeout, J&J adds bispecifics for atopic dermatitis, asthma
Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it
Items per page:
1 - 10 of 1889